All In Biotech

NDA 210797 · Clivunel INC

Scenesse

Afamelanotide · Subcutaneous

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Aug 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Oct 8, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

22

6 Phase 3, 0 recruiting

FAERS reports

21

17 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 11, 2026.

SCENESSE ® is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). SCENESSE is a melanocortin 1 receptor (MC1-R) agonist indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 8, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
  • SCENESSE · AFAMELANOTIDE 16MG · IMPLANT, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Afamelanotide" as an intervention, any sponsor and status, largest first.

All 22 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • anaphylactic reaction4
  • contraindication to medical treatment3
  • type i hypersensitivity3
  • implant site hypersensitivity2
  • implant site pruritus2
  • implant site urticaria2
  • malignant melanoma2
  • vomiting2
  • acute kidney injury1
  • acute on chronic liver failure1
  • appendicitis1
  • ascites1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20201
20212
20224
20232
20244
20255
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 12 on PubMed

Sponsor: Clivunel INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.